Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Combi-Neo
- 10 Feb 2017 Planned number of patients changed from 84 to 78.
- 10 Feb 2017 Status changed from active, no longer recruiting to recruiting.
- 27 Apr 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.